Deal facts
- Buyer
- Milton Chen
- Target
- VSee Lab, Inc.
- Deal value
- Not disclosed
- Announced
- 5 June 2026
- Status
- Completed
- Sector
- Healthcare
- Country
- United States
- Consideration
- shares
Sources
Milton Chen has agreed to acquire the assets of VSee Lab, Inc. in a management buyout structure. The transaction involves consideration in the form of shares, with the deal classified as an asset sale within the Healthcare sector. Both the buyer and the target are based in the United States. Although the specific financial value of the transaction was not disclosed, the deal was announced on 5 June 2026 and subsequently completed on 31 May 2026.
The acquisition marks a significant transition for the healthcare technology firm, allowing the new owner to assume control of the business assets. This arrangement enables the continuation of operations under fresh ownership without the need for a full corporate merger. The transaction is now complete following the finalisation of the asset transfer and share consideration.
More M&A Tools
Explore the Toolkit
Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.
Access nowDeal timeline
1 update- CompletedClosed
Milton Chen completes acquisition of VSee Lab, Inc.
Item 1.01 Entry into a Material Definitive Agreement. On May 31, 2026, VSee Health, Inc., a Delaware corporation (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Milton Chen, the Company’s co-Chief Executive Officer and Chairman of the Board and the Chief Executive Officer of VSee Lab, Inc., a Delaware Corporation and wholly-owned subsidiary of the Company (“
Source
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Laboratory Corporation of America Holdings to acquire BioReference Health, LLC
Laboratory Corporation of America Holdings has agreed to acquire BioReference Health, LLC in a transaction valued at 722 million US dollars. The deal, announced on 14 Oc…
- Buyer
- Laboratory Corporation of America Holdings
- Target
- BioReference Health, LLC
- Deal value
- USD 722,000,000
- Deal type
- asset sale
Silo Pharma, Inc. to acquire Larry King
Silo Pharma, Inc. has completed the acquisition of assets from Larry King. The transaction, which was announced on 14 October 2026, was finalized on 13 October 2026. Bot…
- Buyer
- Silo Pharma, Inc.
- Target
- Larry King
- Deal value
- Not disclosed
- Deal type
- asset sale
Silo Pharma, Inc. to acquire Norsight Consulting Inc.
Silo Pharma, Inc. has agreed to acquire assets from Norsight Consulting Inc. in a transaction announced on 2 October 2026. Both companies are based in the United States…
- Buyer
- Silo Pharma, Inc.
- Target
- Norsight Consulting Inc.
- Deal value
- Not disclosed
- Deal type
- asset sale
JOINT Corp to acquire The Joint Franchises San Antonio, LLC, The Joint Franchises DFW, LLC, The Joint Franchises Houston, LLC, The Joint Franchises Austin, LLC, and The Joint Franchises Texas, Ltd.
JOINT Corp has agreed to acquire a portfolio of five Texas-based entities from The Joint franchise network. The transaction, announced and completed on 1 October 2026, i…
- Buyer
- JOINT Corp
- Target
- The Joint Franchises San Antonio, LLC, The Joint Franchises DFW, LLC, The Joint Franchises Houston, LLC, The Joint Franchises Austin, LLC, and The Joint Franchises Texas, Ltd.
- Deal value
- USD 8,000,000
- Deal type
- asset sale
Element Biosystems, LLC to acquire Standard BioTools Inc.
Element Biosystems, LLC has agreed to acquire Standard BioTools Inc. in a cash asset sale. The transaction was announced on 30 September 2026 and is valued at five milli…
- Buyer
- Element Biosystems, LLC
- Target
- Standard BioTools Inc.
- Deal value
- USD 5,500,000
- Deal type
- asset sale
Buyer history
Milton Chen
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive